 |
| Antihyperlipidemic Drugs |
Hyperlipidemia or high cholesterol is a serious condition that can
significantly increase the risk of heart attacks and strokes if left untreated.
Lifestyle modifications like diet control and exercise can help lower lipid levels
to some extent. However, for many patients with severe hyperlipidemia or those
at very high risk of cardiovascular events, medication becomes essential along
with lifestyle changes. Antihyperlipidemic or lipid-lowering drugs are
important medications that can effectively reduce total cholesterol,
LDL-cholesterol and triglyceride levels in the blood.
Statins - The Cornerstone Lipid-Lowering Agents
Statins are the most commonly prescribed class of medications for lowering high
cholesterol levels. They work by inhibiting an enzyme called HMG-CoA reductase
which is important for cholesterol synthesis in the liver. By blocking this
enzyme, statins reduce cholesterol production and increase LDL receptors
activity which helps clear excess LDL-cholesterol from the blood. Some commonly
used statins include atorvastatin, rosuvastatin, simvastatin, pravastatin etc.
Statins are very effective and can reduce LDL-C levels by about 30-60%
depending on the drug and dose. They also incrementally lower triglyceride
levels. Statins have proven cardiovascular benefits and are first-line agents
as per all major treatment guidelines. Side effects of statins include muscle
pain or weakness (myopathy), liver function abnormalities etc but are generally
well tolerated.
Bile Acid Sequestrants
Bile acid sequestrants like cholestyramine, colestipol and colesevelam work by
binding bile acids in the intestine leading to decreased reabsorption of bile
acids from the small intestine. To maintain the bile acid pool size, more
cholesterol is taken up from the blood by the liver for bile acid synthesis.
This lowers total cholesterol and LDL-cholesterol levels. They are not very
potent but can reduce LDL-C by 15-30%. Common side effects are constipation and
bloating due to their binding actions in the gut. Compliance is also an issue
due to palatability problems.
Cholesterol Absorption Inhibitors
Ezetimibe is the commonly used Antihyperlipidemic
Drugs that selectively blocks intestinal absorption of dietary and
biliary cholesterol. By inhibiting cholesterol absorption from the gut,
ezetimibe reduces hepatic cholesterol levels resulting in clearance of LDL-C
from blood via increased LDL receptor activity in the liver. As a monotherapy,
it reduces LDL-C levels by approximately 15-20%. When combined with a statin,
ezetimibe provides additional LDL-C lowering up to 25%. Being well tolerated,
it finds use in statin-intolerant patients or as an add-on to maximal tolerated
statin therapy.
Niacin (Vitamin B3)
Niacin or nicotinic acid works through multiple mechanisms like inhibiting
hepatic lipoprotein release, activating lipoprotein lipase and reducing
triglyceride synthesis in the liver. It has favorable effects on all lipid
parameters by reducing LDL-C, triglycerides and raising HDL-C levels. However,
its side effect profile has limited its use. Common side effects include skin
flushing, itching, insomnia, dyspepsia and hyperglycemia. Once-daily extended
release formulations have fewer side effects but niacin remains underutilized
due to tolerability issues.
Fibric Acid Derivatives
Fenofibrate, gemfibrozil are fibric acid derivatives used for isolated high
triglyceride levels or mixed dyslipidemia. By activating peroxisome
proliferator-activated receptor alpha (PPAR-α) in the liver, they increases
lipoprotein lipase activity and reduce triglyceride synthesis leading to
reductions in plasma triglyceride and LDL-C levels while raising HDL-C
marginally. Side effects can include gastrointestinal upset and, rarely,
myopathy associated rhabdomyolysis (breakdown of muscle tissue). Monitoring of
liver and muscle enzymes is recommended during treatment.
PCSK9 Inhibitors
A rapidly emerging class, PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9)
inhibitors are monoclonal antibodies (evolocumab, alirocumab) that bind PCSK9
preventing it from degrading liver LDL receptors. By preserving LDL receptors,
PCSK9 inhibitors lead to a marked reduction in LDL-C levels by 50-70% making
them very potent hypolipidemic agents. Currently reserved for patients with
clinical or genetic hypercholesterolemia unable to meet targets with maximum
tolerated statin and ezetimibe combination therapy. Expensive cost currently
limits their more widespread use.
Ongoing Research and Newer Agents
Several novel agents targeting new lipid metabolic pathways and targets like
ANGPTL3 inhibitors, microsomal triglyceride transfer protein inhibitors are
under clinical investigation. Some natural supplement like phytosterols, red
yeast rice are also used albeit their efficacy and safety require further
validation through large controlled clinical trials. With ongoing research,
safer and more effective lipid-lowering therapies will continue to emerge for
patients with hyperlipidemia and dyslipidemia. Lifestyle modifications should
always remain the mainstay for sustainable management even with use of
lipid-lowering drugs.
Different classes of clinically approved
Antihyperlipidemic drugs available for controlling elevated cholesterol and
triglyceride levels through their mechanisms of action. Choice of appropriate
lipid-lowering therapy depends on an individual's lipid profile and
cardiovascular risk factors. Lifestyle modifications and addressing underlying
causes also play a vital adjunct role along with medication to optimize lipid
management for reducing future cardiovascular events. Future research holds
promise for newer targets and safer options in hyperlipidemia management.
Get More Insights On This Topic: https://www.trendingwebwire.com/antihyperlipidemic-drugs-lowering-lipids-to-reduce-cardiovascular-risk/
Explore More Article: https://captionssky.com/industrial-laser-systems-revolutionizing-precision-manufacturing/